Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

SCID
Omenn's Syndrome
Reticular Dysgenesis
Wiskott-Aldrich Syndrome
Bare Lymphocyte Syndrome
Common Variable Immunodeficiency
Chronic Granulomatous Disease
CD40 Ligand Deficiency
Hyper IgM Syndrome
X-linked Lymphoproliferative Disease
Hemophagocytic Lymphohistiocytosis
Griscelli Syndrome
Chediak-Higashi Syndrome
Langerhan's Cell Histiocytosis

Interventions

DRUG: Alemtuzumab 0.3 mg
DRUG: Cyclophosphamide
DRUG: Busulfan
BIOLOGICAL: Stem Cell Transplantation
DRUG: Fludarabine phosphate 40 mg
DRUG: Melphalan
DRUG: Alemtuzumab 0.2 mg
DRUG: Busulfan
DRUG: Fludarabine phosphate 30 mg
DRUG: MESNA

Sponsor

Masonic Cancer Center, University of Minnesota